Core Points - Geoff McDonough, MD will step down as CEO & President and transition to Chair of the Board of Directors, effective October 31, 2025 [1] - Yalonda Howze, JD, currently the Chief Legal Officer, has been appointed as Interim CEO & President [1] - Jason Rhodes will step down as Chair of the Board but will remain a Board Director [1] Company Overview - Generation Bio is a biotechnology company focused on developing redosable therapeutics for T cell-driven autoimmune diseases [2] - The company aims to reprogram T cells in vivo to reduce or eliminate autoreactive T cells that attack the body's own tissues [2] - Generation Bio utilizes cell-targeted lipid nanoparticles (ctLNP) for selective delivery of small interfering RNA (siRNA) to T cells, potentially addressing previously undruggable disease-driving genes in autoimmunity [2]

Core Insights - Generation Bio Co. is focused on developing innovative therapeutics for T cell-driven autoimmune diseases [3] - The company will present at the Jefferies Global Healthcare Conference on June 4, 2025 [1] - A live webcast of the presentation will be available on the company's investor website [2] Company Overview - Generation Bio is developing redosable therapeutics that aim to reprogram T cells in vivo to combat autoimmune diseases [3] - The company utilizes cell-targeted lipid nanoparticles (ctLNP) for selective delivery of small interfering RNA (siRNA) to T cells [3] - This approach targets historically undruggable genes associated with autoimmune diseases, potentially unlocking new treatment avenues [3]